By Kim Han-joo
SEOUL, Dec. 3 (Yonhap) -- South Korean biopharmaceutical firm Celltrion Inc. said Monday that it has sought European approval for the sale of its biosimilar drug Remsima SC.
The European Medicines Agency (EMA) will review Celltrion's application to sell the subcutaneous (SC) version of Remsima, a biosimilar copy of Janssen Biotech, Inc.'s Remicade, the company said.
Remsima, administered through intravascular injections, is used in the treatment of a number of diseases, from rheumatoid arthritis to Crohn's diseas, Celltrion said. The SC version allows patients to conveniently inject it by themselves, unlike the intravenous formulation that requires patients to visit hospitals.
Celltrion forecasts the authorization process to be completed in the second half of 2019.
Celltrion said it intends to improve the competitiveness in the European autoimmune disease therapeutic agent market through the so-called twin-track strategy with the existing Remsima and Remsima SC.
Celltrion said the market share of Remsima surpassed that of its original drug, Remicade, during the fourth quarter of last year to take 52-percent market share.
S. Korea sends strong signal to further stabilize home prices
BOK raises key rate on ballooning household debt
Protectionism, weak SUV lineup major challenges for Hyundai in 2019
Samsung BioLogics case to affect market, delisting unlikely: experts
Finance minister nominee tasked with invigorating economy to spearhead income-led growth strategy